Institution
Pierre-and-Marie-Curie University
Education•Paris, France•
About: Pierre-and-Marie-Curie University is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Raman spectroscopy. The organization has 34448 authors who have published 56139 publications receiving 2392398 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: ForceAtlas2 is a force-directed layout close to other algorithms used for network spatialization, designed for the Gephi user experience, and proposed for the first time as a benchmark for the compromise between performance and quality.
Abstract: Gephi is a network visualization software used in various disciplines (social network analysis, biology, genomics…). One of its key features is the ability to display the spatialization process, aiming at transforming the network into a map, and ForceAtlas2 is its default layout algorithm. The latter is developed by the Gephi team as an all-around solution to Gephi users’ typical networks (scale-free, 10 to 10,000 nodes). We present here for the first time its functioning and settings. ForceAtlas2 is a force-directed layout close to other algorithms used for network spatialization. We do not claim a theoretical advance but an attempt to integrate different techniques such as the Barnes Hut simulation, degree-dependent repulsive force, and local and global adaptive temperatures. It is designed for the Gephi user experience (it is a continuous algorithm), and we explain which constraints it implies. The algorithm benefits from much feedback and is developed in order to provide many possibilities through its settings. We lay out its complete functioning for the users who need a precise understanding of its behaviour, from the formulas to graphic illustration of the result. We propose a benchmark for our compromise between performance and quality. We also explain why we integrated its various features and discuss our design choices.
2,032 citations
TL;DR: The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma, and the glucocorticoid requirement was lower.
Abstract: Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy–temozolomide for the treatment of newly diagnosed glioblastoma. Methods We randomly assigned patients with supratentorial glioblastoma to receive intravenous bevacizumab (10 mg per kilogram of body weight every 2 weeks) or placebo, plus radiotherapy (2 Gy 5 days a week; maximum, 60 Gy) and oral temozolomide (75 mg per square meter of body-surface area per day) for 6 weeks. After a 28-day treatment break, maintenance bevacizumab (10 mg per kilogram intravenously every 2 weeks) or placebo, plus temozolomide (150 to 200 mg per square meter per day for 5 days), was continued for six 4-week cycles, followed by bevacizumab monotherapy (15 mg per kilogram intravenously every 3 weeks) or placebo until the disease progressed or unacceptable toxic effects developed. The coprimary end points were investigator-assessed progression-free survival and overall survival. Results A total of 458 patients were assigned to the bevacizumab group, and 463 patients to the placebo group. The median progression-free survival was longer in the bevacizumab group than in the placebo group (10.6 months vs. 6.2 months; stratified hazard ratio for progression or death, 0.64; 95% confidence interval [CI], 0.55 to 0.74; P<0.001). The benefit with respect to progression-free survival was observed across subgroups. Overall survival did not differ significantly between groups (stratified hazard ratio for death, 0.88; 95% CI, 0.76 to 1.02; P = 0.10). The respective overall survival rates with bevacizumab and placebo were 72.4% and 66.3% at 1 year (P = 0.049) and 33.9% and 30.1% at 2 years (P = 0.24). Baseline health-related quality of life and performance status were maintained longer in the bevacizumab group, and the glucocorticoid requirement was lower. More patients in the bevacizumab group than in the placebo group had grade 3 or higher adverse events (66.8% vs. 51.3%) and grade 3 or higher adverse events often associated with bevacizumab (32.5% vs. 15.8%). Conclusions The addition of bevacizumab to radiotherapy–temozolomide did not improve survival in patients with glioblastoma. Improved progression-free survival and maintenance of baseline quality of life and performance status were observed with bevacizumab; however, the rate of adverse events was higher with bevacizumab than with placebo. (Funded by F. Hoffmann–La Roche; ClinicalTrials.gov number, NCT00943826.)
1,996 citations
TL;DR: The dissection of FoxP3(+) cells into subsets enables one to analyze Treg cell differentiation dynamics and interactions in normal and disease states, and to control immune responses through manipulating particular FoxP 3(+) subpopulations.
1,979 citations
University of Chicago1, Pierre-and-Marie-Curie University2, Lawrence Berkeley National Laboratory3, University of Pennsylvania4, Argonne National Laboratory5, Fermilab6, African Institute for Mathematical Sciences7, University of Cape Town8, Texas A&M University9, University of Portsmouth10, University of Cambridge11, University of Toronto12, Wayne State University13, University of Colorado Boulder14, University of Tokyo15, California Institute of Technology16, University of Victoria17, University of California, Berkeley18, University of Illinois at Urbana–Champaign19, Autonomous University of Barcelona20, University of Chile21, Stockholm University22, University of Texas at Austin23, Princeton University24, University of Oxford25, University of California, Santa Barbara26, Las Cumbres Observatory Global Telescope Network27, Rutgers University28, University of Copenhagen29, Australian Astronomical Observatory30, Instituto Superior Técnico31, University of Utah32, Rochester Institute of Technology33, Space Telescope Science Institute34, Johns Hopkins University35, Pennsylvania State University36, University of the Western Cape37, University of Southampton38
TL;DR: In this article, the authors presented cosmological constraints from a joint analysis of type Ia supernova (SN Ia) observations obtained by the SDSS-II and SNLS collaborations.
Abstract: Aims. We present cosmological constraints from a joint analysis of type Ia supernova (SN Ia) observations obtained by the SDSS-II and SNLS collaborations. The dataset includes several low-redshift samples (z< 0.1), all three seasons from the SDSS-II (0.05
1,939 citations
Charles University in Prague1, University of Regensburg2, First Faculty of Medicine, Charles University in Prague3, Imperial College London4, University of Hertfordshire5, Pierre-and-Marie-Curie University6, Autonomous University of Barcelona7, Netherlands Cancer Institute8, Medical University of Vienna9, European Association of Urology10, Medical University of Graz11
TL;DR: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice and the stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment.
1,910 citations
Authors
Showing all 34671 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Zhong Lin Wang | 245 | 2529 | 259003 |
| Guido Kroemer | 236 | 1404 | 246571 |
| Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
| J. E. Brau | 162 | 1949 | 157675 |
| E. Hivon | 147 | 403 | 118440 |
| Kazuhiko Hara | 141 | 1956 | 107697 |
| Simon Prunet | 141 | 434 | 96314 |
| H. J. McCracken | 140 | 579 | 71091 |
| G. Calderini | 139 | 1734 | 102408 |
| Stefano Giagu | 139 | 1651 | 101569 |
| Jean-Paul Kneib | 138 | 805 | 89287 |
| G. Marchiori | 137 | 1590 | 94277 |
| J. Ocariz | 136 | 1562 | 95905 |
| Jean-Marie Tarascon | 136 | 853 | 137673 |
| Alexis Brice | 135 | 870 | 83466 |